KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) EBIT Margin: 2010-2024

Historic EBIT Margin for Emergent BioSolutions (EBS) over the last 15 years, with Dec 2024 value amounting to -10.42%.

  • Emergent BioSolutions' EBIT Margin rose 1115.00% to 33.10% in Q3 2025 from the same period last year, while for Sep 2025 it was 15.02%, marking a year-over-year increase of 3055.00%. This contributed to the annual value of -10.42% for FY2024, which is 5881.00% up from last year.
  • As of FY2024, Emergent BioSolutions' EBIT Margin stood at -10.42%, which was up 84.95% from -69.23% recorded in FY2023.
  • Emergent BioSolutions' 5-year EBIT Margin high stood at 27.80% for FY2020, and its period low was -69.23% during FY2023.
  • Moreover, its 3-year median value for EBIT Margin was -15.21% (2022), whereas its average is -31.62%.
  • Its EBIT Margin has fluctuated over the past 5 years, first plummeted by 5,401bps in 2023, then soared by 5,881bps in 2024.
  • Emergent BioSolutions' EBIT Margin (Yearly) stood at 27.80% in 2020, then slumped by 855bps to 19.25% in 2021, then slumped by 3,446bps to -15.21% in 2022, then tumbled by 5,401bps to -69.23% in 2023, then spiked by 5,881bps to -10.42% in 2024.